Daniel L Suzman

12PUBLICATIONS
96CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology not elsewhere classifiedPharmacogenomicsPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 12, 2026
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

|Feb 12, 2026
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.

Nooshin Mirkheshti, Daniel Edem Kpormegbey, Chana Weinstock

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Jul 17, 2025
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

William F Maguire, Dow-Chung Chi, Sundeep Agrawal

|Dec 20, 2024
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.

Laronna Colbert, Yuxia Jia, Anurag Sharma

|Sep 09, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.

Jaleh Fallah, Brian L Heiss, Hee-Koung Joeng

Pageof 2

Frequent Collaborators

11 joint publications

Laleh Amiri-Kordestani

9 joint publications

Paul G Kluetz

9 joint publications

Richard Pazdur

8 joint publications

William F Pierce